|
1
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hori M, Matsuda T, Shibata A, Katanoda K,
Sobue T and Nishimoto H; Japan Cancer Surveillance Research Group,
: Cancer incidence and incidence rates in Japan in 2009: A study of
32 population-based cancer registries for the Monitoring of Cancer
Incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 45:884–891.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Watanabe T, Muro K, Ajioka Y, Hashiguchi
Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S,
et al: Japanese society for cancer of the colon and rectum (JSCCR)
guidelines 2016 for the treatment of colorectal cancer. Int J Clin
Oncol. 23:1–34. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rutman RJ, Cantarow A and Paschkis KE:
Studies in 2-acetylaminofluorene carcinogenesis. III. The
utilization of uracil-2-C14 by preneoplastic rat liver and rat
hepatoma. Cancer Res. 14:119–123. 1954.PubMed/NCBI
|
|
5
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liu W, Fang Y, Wang XT, Liu J, Dan X and
Sun LL: Overcoming 5-Fu resistance of colon cells through
inhibition of Glut1 by the specific inhibitor WZB117. Asian Pac J
Cancer Prev. 15:7037–7041. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dallas NA, Xia L, Fan F, Gray MJ, Gaur P,
van Buren G II, Samuel S, Kim MP, Lim SJ and Ellis LM:
Chemoresistant colorectal cancer cells, the cancer stem cell
phenotype, and increased sensitivity to insulin-like growth
factor-I receptor inhibition. Cancer Res. 69:1951–1957. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoshida M, Horiguchi H, Kikuchi S, Iyama
S, Ikeda H, Goto A, Kawano Y, Murase K, Takada K, Miyanishi K, et
al: miR-7977 inhibits the Hippo-YAP signaling pathway in the bone
marrow mesenchymal stromal cells. PLoS One. 14:e02132202019.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ryan J and Letai A: BH3 profiling in whole
cells by fluorimeter or FACS. Methods. 61:156–164. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fraser C, Ryan J and Sarosiek K: BH3
profiling: A functional assay to measure apoptotic priming and
dependencies. Methods Mol Biol. 1877:61–76. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tao ZF, Hasvold L, Wang L, Wang X, Petros
AM, Park CH, Boghaert ER, Catron ND, Chen J, Colman PM, et al:
Discovery of a potent and selective BCL-XL inhibitor with in vivo
activity. ACS Med Chem Lett. 5:1088–1093. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jian YS, Chen CW, Lin CA, Yu HP, Lin HY,
Liao MY, Wu SH, Lin YF and Lai PS: Hyaluronic acid-nimesulide
conjugates as anticancer drugs against CD44-overexpressing HT-29
colorectal cancer in vitro and in vivo. Int J Nanomedicine.
12:2315–2333. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dutta S, Ryan J, Chen TS, Kougentakis C,
Letai A and Keating AE: Potent and specific peptide inhibitors of
human pro-survival protein Bcl-xL. J Mol Biol. 427:1241–1253. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Foight GW, Ryan JA, Gullá SV, Leta A and
Keating AE: Designed BH3 peptides with high affinity and
specificity for targeting Mcl-1 in cells. ACS Chem Biol.
9:1962–1968. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Montero J and Letai A: Why do BCL-2
inhibitors work and where should we use them in the clinic? Cell
Death Differ. 25:56–64. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nita ME, Nagawa H, Tominaga O, Tsuno N,
Fujii S, Sasaki S, Fu CG, Takenoue T, Tsuruo T and Muto T:
5-Fluorouracil induces apoptosis in human colon cancer cell lines
with modulation of Bcl-2 family proteins. Br J Cancer. 78:986–992.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhao DP, Ding XW, Peng JP, Zheng YX and
Zhang SZ: Prognostic significance of bcl-2 and p53 expression in
colorectal carcinoma. J Zhejiang Univ Sci B. 6:1163–1169. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu DW, Huang CC, Chang SW, Chen TH and Lee
H: Bcl-2 stabilization by paxillin confers 5-fluorouracil
resistance in colorectal cancer. Cell Death Differ. 22:779–789.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vo TT, Ryan J, Carrasco R, Neuberg D,
Rossi DJ, Stone RM, Deangelo DJ, Frattini MG and Letai A: Relative
mitochondrial priming of myeloblasts and normal HSCs determines
chemotherapeutic success in AML. Cell. 151:344–355. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan
JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P,
Tai YT, et al: Pretreatment mitochondrial priming correlates with
clinical response to cytotoxic chemotherapy. Science.
334:1129–1133. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kubo T, Kawano Y, Himuro N, Sugita S, Sato
Y, Ishikawa K, Takada K, Murase K, Miyanishi K, Sato T, et al: BAK
is a predictive and prognostic biomarker for the therapeutic effect
of docetaxel treatment in patients with advanced gastric cancer.
Gastric Cancer. 19:827–838. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Klotz DM, Nelson SA, Kroboth K, Newton IP,
Radulescu S, Ridgway RA, Sansom OJ, Appleton PL and Näthke IS: The
microtubule poison vinorelbine kills cells independently of mitotic
arrest and targets cells lacking the APC tumour suppressor more
effectively. J Cell Sci. 125:887–895. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan Y, Xie R, Zhang Q, Zhu X, Han J and
Xia R: Bcl-xL/Bak interaction and regulation by miRNA let-7b in the
intrinsic apoptotic pathway of stored platelets. Platelets.
30:75–80. 2019. View Article : Google Scholar : PubMed/NCBI
|
